Cargando…

Chemokine receptors: multifaceted therapeutic targets

Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor w...

Descripción completa

Detalles Bibliográficos
Autor principal: Proudfoot, Amanda E. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097668/
https://www.ncbi.nlm.nih.gov/pubmed/11910892
http://dx.doi.org/10.1038/nri722
_version_ 1783511033560694784
author Proudfoot, Amanda E. I.
author_facet Proudfoot, Amanda E. I.
author_sort Proudfoot, Amanda E. I.
collection PubMed
description Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor was discovered, and the rapidly expanding number of antagonists holds promise for new medicines to combat diseases that are currently incurable. Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system.
format Online
Article
Text
id pubmed-7097668
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70976682020-03-26 Chemokine receptors: multifaceted therapeutic targets Proudfoot, Amanda E. I. Nat Rev Immunol Article Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor was discovered, and the rapidly expanding number of antagonists holds promise for new medicines to combat diseases that are currently incurable. Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system. Nature Publishing Group UK 2002 /pmc/articles/PMC7097668/ /pubmed/11910892 http://dx.doi.org/10.1038/nri722 Text en © Nature Publishing Group 2002 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Proudfoot, Amanda E. I.
Chemokine receptors: multifaceted therapeutic targets
title Chemokine receptors: multifaceted therapeutic targets
title_full Chemokine receptors: multifaceted therapeutic targets
title_fullStr Chemokine receptors: multifaceted therapeutic targets
title_full_unstemmed Chemokine receptors: multifaceted therapeutic targets
title_short Chemokine receptors: multifaceted therapeutic targets
title_sort chemokine receptors: multifaceted therapeutic targets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097668/
https://www.ncbi.nlm.nih.gov/pubmed/11910892
http://dx.doi.org/10.1038/nri722
work_keys_str_mv AT proudfootamandaei chemokinereceptorsmultifacetedtherapeutictargets